top left cornertop right corner
Blackburn with Darwen Primary Care Trust - About Us

Medicines Management Board Minutes

The Medicines Management Board meet on a monthly basis to discuss and make decisions on new medicines and policies. 


The upcoming dates for 2014/2015 are: 


  • Wednesday 19th Nov 2014

  • Wednesday 17th Dec 2014

  • Wednesday 21st Jan 2015

  • Wednesday 25th Feb 2015

  • Wednesday 25th Mar 2015

  • Wednesday 22nd Apr 2015

  • Wednesday 20th May 2015

  • Wednesday 17th June 2015

  • Wednesday 15th July 2015

  • Wednesday 19th Aug 2015

  • Wednesday 16th Sept 2015

  • Wednesday 21st Oct 2015

  • Wednesday 18th Nov 2015

  • Wednesday 16th Dec 2015


Below you will find the minutes from each of the meetings from January 2010 onwards. The minutes from subsequent meetings will be added as soon as they become available. 


Current Year - Medicines Management Board Minutes

application/pdfMedicine Management Board Minutes Feb 2015 (134 KB)27/04/2015Download
 Sugammadex approved for use by Consultant Anaethetist only. Branded Generics for Oxycodone, Fentanyl patches, Isosorbide mononitrate MR, and mebeverine to be included in formulary Vedolizumab for Crohn's Disease – : BLACK Spironolactone for Acne Vulgaris –Traffic Light: RED SSRI's in Premature Ejaculation (PE) – Traffic Light: Amber Dapoxetine for Premature Ejaculation (PE) – is not recommended due to lack of cost and clinical effective evidence, long-term safety concerns and short-acting nature 
application/pdfMedicine Management Board Minutes Jan 2015 (147 KB)27/04/2015Download
 December 2014 meeting postponed so actions carried forward and discussed Jan 2015 Formulary Updates – Fulvestrant (Faslodex) – Consultant has agreed that patients on Faslodex can be referred to clinic for review. Formulary updates – Mirabegron – awaiting response for guidance on choice of treatment for urinary incontinence for use by Primary care clinicians. Nicardipine approved for use on critical care unit. Lacosamide approved for specialist paediatric use. Traffic light: RED  
application/pdfELHE Medicines Management Board Minutes November 2014 (172 KB)03/02/2015Download
 Lisdexamphetamine- treatment of ADHD in children and adults only in complex patients who meet two specific criteria- RED Traffic Light. Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma – is recommended as an option by NICE (TAG 321) - RED Traffic Light. Mexiletine - ventricular tachycardia when other licensed treatments have been unsuccessful - approved for specialist cardiology use RED Traffic Light.  
application/pdfMedicines Management Board Minutes October 2014 (177 KB)02/12/2014Download
 Vitamin D Guidleuines - children approved. Brimonidine gel - symptomatic persistent facial erythema of rosacea - BLACK traffic light . Opthalmology Macular pathways - approved. Subcutaneous Tocilzumab - alternative to intravenous tocilizumab providing patient meets the prescribing criteria as set out in NICE technology appraisals for 1st, 2nd & 3rd line use to treat active rheumatoid arthritis and the agreed Lancashire Rheumatology Alliance flex for use as monotherapy - RED traffic light. RA 
application/pdfMedicine Management Board Minutes 17th September 2014 (190 KB)03/11/2014Download
 ELHT Vitamin D Guidelines – Children - approved for use. Rifaximin added to formulary for hepatic encephalopathy, for consultant gastroenterologist use only and a protocol. Traffic light: RED Simeprevir to be included in formulary if NICE approve in January. Pentoxifylline & Vitamin E for osteonecrosis of the jaw approved subject to satisfactory supply arrangements. Osvaren included in formulary for renal use. Traffic Light: AMBER Certolizumab - of adults with ankylosing spondylitis in line 
application/pdfMedicines Management Board Minutes 16th July 2014 (173 KB)07/10/2014Download
 Vesomni (solifenacin 6mg/tamsulosin 400mcg MR) - moderate to severe storage symptoms & voiding symptoms associated with benign prostatic hypoplasia - BLACk traffic light. Lubiprostone - adults with chronic idiopathic constipation - BLACK traffic light. Certolizumab -treatment of adults with active & progressive psoriatic arthritis in line with NICE TA199 - RED Traffic Light. Armour Thyroid - unlicensed product - BLACK traffic light. Canagliflozin - in combination therapy for treatment of typ 
application/pdfMedicine Management Board Minutes 21st May 2014 (179 KB)31/07/2014Download
 NOAC's position Statement - The position statement with a preferred option NOAC will not be pursued and all three will be available for prescribing, with traffic light remaining Amber. NEW PRODUCT REQUESTS – CARBETOCIN and AZARGA EYE DROPS- deferred  
application/pdfMedicines Management Board Minutes 18.06.2014 (183 KB)31/07/2014Download
 NEW PRODUCT REQUESTS – CARBETOCIN - formulary for use following elective caesarean section Traffic Light: RED AZARGA EYE DROPS - second line when dorzolamide/timolol combination is not tolerated - Traffic Light: GREEN  
application/pdfMedicines Management Board Minutes 16th April 2014 (226 KB)12/06/2014Download
 New Product Requests -Glycopyrronium for hyperhidrosis. Denosumab in prostate cancer. Hyoscine, melatonin Shared Care Protocol. NOAC's position Statement for East Lancashire Health Economy . New Product Request – Ostenil Plus. Erectile Dysfunction Guidelines. Blood Glucose Testing devices for Paediatrics. Unlicensed Request –Testosterone Gel, ELHT – JOINT CATHETER CARE FORMULARY. NEW PRODUCT REQUEST – BROMFENAC EYE DROPS. Denosumab Shared Care Guidelines. Strontium Ranelate. Indapamide, NICE REC 
application/pdfMedicines Management Board Minutes 19th March 2014 (183 KB)06/05/2014Download
 Xiapex Policy and Form updated. ELHT bowel prepartion PIL finalised. ELHT Fosfomycin for UTI protocol - joint letter to be sent to GPs. New product Request - Ostenil Plus - rejected. ED Guidelines completed. Unlicensed Request - Pilocarpine for dry mouth on specialist palliative care initiation - AMBER traffic light. ELHT medicines policy updated and acknowledged by ELMMB. Dapoxetine - was BLACK traffic light now Grey Under Review. Fluarix Tetra - Grey under review awaiting guidance from N 
application/pdfMedicines Management Board Minutes February 2014 (196 KB)25/03/2014Download
 New product request Ostenil Plus - not approved for osteoarthritis. MSK service to be informed that hyaluronon injections should not be used. Traffic light: BLACK Golimumab for moderate to severe ulcerative colitis - Traffic Light: BLACK Omega 3 Fatty Acids Post MI position Statement - updated position statement accepted for use in ELHE. MEDICINES RECONCILIATION POLICY updated and accepted by ELMMB. To be incorporated into current Health Economy Transfer of Care Policy. ELHT updated Breastf 
application/pdfMedicines Management Board Minutes January 2014 (189 KB)25/03/2014Download
 Xiapex Policy and form updated. ELHT bowel preparation PIL's updated New product request - Pivmecillinam - approved for use in UTI on microbiology advice - AMBER traffic light. Lidocaine & Fluorescein unit dose eye drops - added to fornulary -RED traffic light. Proxymetacaine unit dose eye drops - added to formulary - RED traffic light. Strontium ranelate sachets - removed from formulary following recent EMA recommendations. ELHT prescribing accuracy audit acknowledged by ELMMB.  
Page: [1] [2] [3] [4]
[ Next » ]

Archived Medicine Management Board Meeting Minutes

application/pdfMedicines Management Board Meeting 21st January 2010 (43 KB)19/07/2010Download
application/pdfMedicines Management Board Meeting 25th February 2010 (43 KB)19/07/2010Download
application/pdfMedicines Management Board Meeting 25th March 2010 (37 KB)19/07/2010Download
application/pdfMedicines Management Board Meeting 22nd April 2010 (44 KB)19/07/2010Download
 ** Vitamin D; Immunoglobulin; Oxycodone; Dementia; Hyaluronic Acid; Venlafaxine MR; Ranolazine; Aliskeren; pain releif protocol for patients dependent on opiates; Magnesium aspartate; Mesalazine preparations; Pramipexole MR;  
application/pdfMedicines Management Board Meeting 20th May 2010 (83 KB)19/07/2010Download
 ** Immunoglobulin; Oxycodone; Dementia; Hyaluronic Acid; Venlafaxine MR; Ranolazine; Aliskeren; Pain releief protocol for patients dependent on opiates; Vitamin D; PbR exclusions list; good prescribing guidelines; Clopidogrel & PPI; CAMET recommendations; Neuropathic Pain; Genotropin; Omnitrope; Anti-TNF; CQUIN; Specials; Tenofovir; Betesil;  
application/pdfMedicines Management Board Meeting 17th June 2010 (43 KB)19/07/2010Download
 ** Immunoglobulin; Oxycodone; Dementia; Hyaluronic Acid; Venlafaxine MR; Ranolazine; Aliskeren; Pain releif protocol for patients dependent on opioids; Magnesium aspartate; Vitamin D; Pramipexole MR; Good prescribing guidelines; Clopidogrel and PPI; Neuropathic Pain; Anti-TNF; Palliative Care Guidelines; Priority setting of medicines; Silver dressings; Sorafenib; Pemetrexed; Glucosamine; Neonatal Medicines formulary; Sugammadex; Transvasin Cream; Continence formulary;  
application/pdfMedicines Management Board Meeting 15th July 2010 (43 KB)31/08/2010Download
 ** Rituximab; Oxycodone; Dementia; Hyaluronic acid; Venlafaxine MR; Ranolazine; Aliskeren; Viatmin D guidelines; Pramipexole MR; Good prescribing guidelines; Neuropathic Pain; Continence and catheter care formulary; High priority medicines for monitoring; Prucalopride; Phenobarbitone liquid; Chloral Hydrate; Vigabatrin; Potassium canrenoate; Chlorthiazide liquid; Spironolactone liquid; Tobramycin injection; Lercanidipine, Colecalciferol Dekristol; Metformin SR; Quixil Evicel; NPSA LMWH; Red traf 
application/pdfMedicines Management Board Meeting 19th August 2010 (41 KB)11/10/2010Download
 ** Oxycodone; Dementia; Hyaluronic acid; Venlafaxine MR; Aliskeren; Ranolazine; Magnesium Aspartate; Good prescribing guidelines; Priority setting of medicines; Saxagliptin; Sativex; Amifampridine Firdapse; Dutasteride; Diabetes sub-cut insulin chart; Erectile dysfunction policy; MERLOT trial; Nebusal; 
application/pdfMedicines Management Board Meeting 16th September 2010 (38 KB)11/10/2010Download
 ** Oxycodone; Dementia; Hyaluronis Acid; Priority setting of medicines; Saxagliptin; Nebusal; Withdrawal of Mixtard; Lipid modification; Goserelin; MMB governance controls; Prescribing accuracy; Contraception formulary; Roflumilast & Indacaterol; Arthrotec; Simvastatin Liquid; Secretin; Good prescribing guidelines; Abatacept; Tocilizumab; Dronedarone; 
application/pdfMedicines Management Board Meeting 20th October 2010 (38 KB)06/12/2010Download
 ** Mixtard withdrawal; Oxycodone; Demetia; Hyaluronic Acid; Priority setting of medicines; Anti-TNF's; Wound care formulary; Opioid choice for syringe driver; Cancer drugs fund; Lithium; Modafinil; Implanon; Nexplanon;  
application/pdfMedicines Management Board Meeting 17th November 2010 (46 KB)21/04/2011Download
 ** Modafinil; Oxycodone; Dementia treated with antipsychotics; Hyaluronic Acid; MMB governance controls; COPD guidelines; Atimos Modulite; Ranolazine; Aliskeren; Anti-TNF; Saxagliptin; Prescribing Accuracy; Specials; Ulipristal Ellaone; Co-careldopa gel; Teriparetide; Paediatric specials; Prednisolone EC 5mg tablets; Potassium permanganate; Movelat; Algesal; Eltrombopag; Ofatamumab; Bendamustine; Temsirolimus; Denosumab; Midwifery prescribing and exemption; Bowel preparations; 
application/pdfMedicines Management Board Meeting 15th December 2010 (40 KB)21/04/2011Download
 ** Aliskeren; oxycodone; Demetia treated with antipsychotics; MMB governance controls; Ranolazine; Anti-TNF; NICE MM Sub group; Midwives exemptions; Paediatric specials; Tobramycin Bramitob; Omalizumab; Mycophenolate; Adrenaline autopen Jext; Premarin; Ovestin; Topical NSAIDS; Black light medicines; Bowel Preparations; Food First;  
All material in this section is aimed at health professionals, but is information currently held within the public domain.   Members of the public seeking advice on medicine-related matters are encouraged to speak with their GP, pharmacist or nurse, or contact NHS Direct on 0845 46 47.  

Richard Lee, East Lancashire Health Economy New Drugs Pharmacist.


Powered by EasySite™ Content Management System